Strona główna・Stock List・Merck & Co Inc.

Merck & Co Inc.

Closed

SectorHealthcare

130.3 -0.41

Buy Sell

Overview

Share price change

24h

Current

Min

129.69

Max

132.76

Key metrics
By Trading Economics
Income	-7.2B -4.2B
Sales	-114M 16B
P/E Sector Avg	35.992 68.51
EPS	-1.28
Dividend yield	2.52
Profit margin	-26.053
Employees	73,000
EBITDA	-6.4B -2B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+6.13% upside

Dividends
By Acuity
Dividend yield Sector Avg	2.52% 2.29%
Next Earnings	29 paź 2026
Next Dividend date	7 paź 2026
Next Ex Dividend date	15 wrz 2026

Market Stats
By TradingEconomics
Market Cap	35B 307B
Previous open	130.71
Previous close	130.3

News Sentiment

By Acuity

52%

48%

247 / 340 Ranking in Healthcare

Merck & Co Inc. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 sie 2026, 19:36 UTC

Social Media

News

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

7 sie 2026, 22:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

6 sie 2026, 23:01 UTC

Event

Merck & Co Inc shares are trading lower in after-market hours following the FDA's acceptance of a supplemental application for ENFLONSIA™.

5 sie 2026, 19:43 UTC

News

Social Media

Merck & Co. received Health Canada approval for Keytruda, yet shares are lower amid mixed market sentiment following disappointing ADP employment data.

4 sie 2026, 23:26 UTC

News

Merck & Co Inc reported a Q2 net loss of $1.3 billion. Shares are higher in after-market hours amid broader market gains from oil supply negotiations.

3 sie 2026, 20:03 UTC

News

Social Media

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31 lip 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

30 lip 2026, 20:09 UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

29 lip 2026, 23:41 UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

28 lip 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

27 lip 2026, 20:06 UTC

Social Media

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

24 lip 2026, 18:56 UTC

News

Social Media

Merck & Co Inc. announced a strategy to enhance access to its HIV prevention drug Alimatravir across 129 countries, boosting shares during Friday's session.

22 lip 2026, 19:46 UTC

Social Media

Merck & Co Inc shares are higher, supported by strong contract performance valued at $1,000. The stock remains near its one-month high amid broader market challenges.

21 lip 2026, 19:56 UTC

News

Social Media

Merck & Co. Inc. shares are rising following positive Phase 3 trial results for its once-weekly oral HIV treatment regimen, islatravir and lenacapavir.

20 lip 2026, 20:02 UTC

Social Media

Merck & Co. shares are lower as the pharmaceutical sector faces pressure. The company plans to price Lipfendra at $10.50 per day.

Peer Comparison

Price change

Merck & Co Inc. Forecast

Price Target

By TipRanks

6.13% upside

12 Months Forecast

Average 138.94 USD 6.13%

High 155 USD

Low 100 USD

Based on 17 Wall Street analysts offering 12 month price targets forMerck & Co Inc. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

Buy

Hold

Sell

Based on 17 analysts giving stock ratings to Merck & Co Inc. - Dist in the past 3 months.

Sentiment

By Acuity

247 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.